person · Reporting owner
De Paolantonio Ernest Robert
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODELIVERY SCIENCES INTERNATIONAL INCBDSI · Entity 128876 | CFO, Secretary and Treasurer | December 04, 2018 | December 06, 2018 |
| Teligent, Inc.TLGT · Entity 134764 | Chief Financial Officer | April 15, 2021 | April 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date December 04, 2018 · Filed December 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 140,548 |
Reported balance
After 2018-12-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-12-04 · Sale · Disposed 16,161 · Balance 140,548 F1: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2: On November 4, 2018, the Reporting Person sold an aggregate of 16,161 shares of the Issuer's Common Stock at a weighted average price of $3.79 per share. The highest sale price for the Common Stock was $3.84 per share and the lowest sale price was $3.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
F2: On November 4, 2018, the Reporting Person sold an aggregate of 16,161 shares of the Issuer's Common Stock at a weighted average price of $3.79 per share. The highest sale price for the Common Stock was $3.84 per share and the lowest sale price was $3.76 per share.
Teligent, Inc.
Report date April 15, 2021 · Filed April 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2031-04-15 | Direct | 240,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 240,000 · Balance 240,000 F2: These securities were issued as an inducement to the Reporting Person to enter into employment with the Registrant. F1: The shares underlying the derivative securities shall vest on the third anniversary of the date of grant contingent upon (a) the Reporting Person's continued employment with the Registrant and (b) subject to achieving certain performance criteria. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2031-04-15 | Direct | 195,000 |
Reported balance
After 2021-04-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-15 · Grant · Acquired 195,000 · Balance 195,000 F3: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2: These securities were issued as an inducement to the Reporting Person to enter into employment with the Registrant. F4: One-fourth of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 15, 2022 contingent upon the Reporting Person's employment with the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the derivative securities shall vest on the third anniversary of the date of grant contingent upon (a) the Reporting Person's continued employment with the Registrant and (b) subject to achieving certain performance criteria.
F2: These securities were issued as an inducement to the Reporting Person to enter into employment with the Registrant.
F3: Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
F4: One-fourth of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 15, 2022 contingent upon the Reporting Person's employment with the Registrant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Journey Medical Corp
Report date October 04, 2022 · Filed March 01, 2023 · Amendment
Section 16 reporting ended · disclosed 2023-03-01. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 259,907 |
Reported balance
After 2022-10-04 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2022-10-04 · Sale · Disposed 10,093 · Balance 259,907 F1: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F3: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F2: Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct. F4: Includes restricted stock units, which vest over various time periods. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
F2: Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct.
F3: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: Includes restricted stock units, which vest over various time periods.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2022 Filed Oct 6, 2022 16:30 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 10,093 | $2.41 | $24,324.13 |
DisclosureSEC source: 0001104659-22-106787 · tm2227683-1_4seq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,907 F1 · shares: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| October 04, 2022 Filed Mar 1, 2023 21:46 UTC Amendment | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 10,093 | $2.41 | $24,324.13 |
DisclosureSEC source: 0001104659-23-027555 · tm237728-1_4aseq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,907 F1 · shares: In connection with the vesting of 40,000 shares on October 1, 2022, a total of 10,093 of such shares were sold by the Issuer in order to satisfy the Reporting Person's tax withholding obligations. The Reporting Person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock. F3 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 4, 2022, was $2.38 to $2.43. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · acquired: Due to a clerical error, the original Form 4 filed on October 6, 2022 reflected an acquisition of 10,029 shares in lieu of a disposition of 10,029 shares. The amount of securities beneficially owned following the reported transaction reported in the previously filed Form 4 is correct. F4 · balance_after: Includes restricted stock units, which vest over various time periods. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 09:32 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082285 · tm2221508-1_4seq1.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 F1 · shares: On July 21, 2022, the reporting person was granted 150,000 restricted stock units pursuant to the Issuer's 2015 Stock Plan. One-fourth of the shares will vest on each of July 21, 2023, 2024, 2025 and 2026, subject to the reporting person's continuous service with the Issuer. F2 · balance_after: Includes restricted stock units, 150,000 of which will vest over various time periods as set forth in footnote 1, and 120,000 of which will vest in three increments as follows: (1) 40,000 units on October 1, 2022, (2) 40,000 units on October 1, 2023, and (3) 40,000 units on October 1, 2024. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 16:47 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCOMMON STOCK | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042272 · tm2211324-7_4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 F1 · shares: The 120,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 40,000 units on October 1, 2022, (2) 40,000 units on October 1, 2023, and (3) 40,000 units on October 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 09:03 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantRestricted Stock Units · Derivative | 195,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-051156 · tm2113137-2_4seq1.xml · derivative · entry 2 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-04-15 F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · price: These securities were issued as an inducement to the Reporting Person to enter into employment with the Registrant. F4 · derivative.exercise_date: One-fourth of the shares underlying the derivative securities shall vest ratably on an annual basis beginning on April 15, 2022 contingent upon the Reporting Person's employment with the Registrant. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 09:03 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 240,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001104659-21-051156 · tm2113137-2_4seq1.xml · derivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2031-04-15 F2 · price: These securities were issued as an inducement to the Reporting Person to enter into employment with the Registrant. F1 · derivative.exercise_date: The shares underlying the derivative securities shall vest on the third anniversary of the date of grant contingent upon (a) the Reporting Person's continued employment with the Registrant and (b) subject to achieving certain performance criteria. Read SEC document |
| December 04, 2018 Filed Dec 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 16,161 | $3.79 | $61,250.19 |
DisclosureSEC source: 0000899243-18-030296 · doc4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,548 F1 · security: The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F2 · price: On November 4, 2018, the Reporting Person sold an aggregate of 16,161 shares of the Issuer's Common Stock at a weighted average price of $3.79 per share. The highest sale price for the Common Stock was $3.84 per share and the lowest sale price was $3.76 per share. Read SEC document |
| April 06, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 33,255 | $2.06 | $68,505.30 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 7 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,709 F6 · kind: The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs. F8 · price: On April 6, 2018, the Reporting Person sold an aggregate of 33,255 shares of the Issuer's Common Stock at a weighted average price of $2.06 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 30,900 | $2.12 | $65,508.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 6 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,864 F6 · kind: The shares of common stock were sold by the Reporting Person upon expiration of a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's additional tax liability upon the vesting of the Reporting Person's RSUs. F7 · price: On April 5, 2018, the Reporting Person sold an aggregate of 30,900 shares of the Issuer's Common Stock at a weighted average price of $2.12 per share. The highest sale price for the Common Stock was $2.15 per share and the lowest sale price was $2.08 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 27,075 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · derivative · entry 12 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,075 shares Expires 2020-02-06 F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. F5 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 31,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · derivative · entry 11 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,333 Underlying: Common Stock · 31,667 shares Expires 2020-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · derivative · entry 10 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019. F3 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 34,391 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · derivative · entry 9 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,391 shares Expires 2018-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. F2 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 1,267 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · derivative · entry 8 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,267 shares Expires 2018-04-03 F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. F1 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 27,075 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 5 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the performance-based RSUs ("Performance RSUs") granted to the Reporting Person on February 6, 2017 under the EIP subject to certain performance measures. The remainder of the Performance RSUs under this grant will vest, in equal amounts, but subject to certain performance measures, after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 31,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 4 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 6, 2017 under the EIP. The remainder of the RSUs under this grant will vest in equal portions after the first open window upon the filing of the Company's Annual Report in March 2019 and March 2020. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 3 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs that were granted to the Reporting Person on February 29, 2016, pursuant to a grant under the EIP. The remainder of the RSUs under this grant will vest on March 1, 2019. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 34,391 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 2 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended (the "EIP"). Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. Read SEC document |
| April 03, 2018 Filed Apr 6, 2018 18:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 1,267 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-009681 · doc4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,731 F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long-Term Incentive Plan. Read SEC document |
| February 18, 2018 Filed Feb 23, 2018 19:22 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 70,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-005382 · doc4.xml · derivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2021-03-19 F1 · kind: The RSUs were issued to the Reporting Person on February 18, 2018, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the first open trading window of 2019; (ii) one-third vests on the date of the first open trading window of 2020; and (iii) the remaining third vests on the first open trading window of 2021. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. F1 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 18, 2018, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the first open trading window of 2019; (ii) one-third vests on the date of the first open trading window of 2020; and (iii) the remaining third vests on the first open trading window of 2021. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 170 | $1.90 | $323.00 |
DisclosureSEC source: 0000899243-17-008548 · doc4.xml · nonDerivative · entry 2 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,464 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 469 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008548 · doc4.xml · derivative · entry 3 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 469 shares Expires 2017-03-22 F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 469 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008548 · doc4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,634 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · derivative · entry 9 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 30,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 2,650 | $2.03 | $5,379.50 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 6 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,165 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F7 · price: On March 1, 2017, the Reporting Person sold an aggregate of 2,650 shares of the Issuer's Common Stock at a weighted average price of $2.03 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 5 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 34,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · derivative · entry 8 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,391 Underlying: Common Stock · 34,392 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 13,800 | $1.95 | $26,910.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 4 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,815 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F5 · price: On February 23, 2017, the Reporting Person sold an aggregate of 13,800 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.10 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 34,392 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 3 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 8,532 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · derivative · entry 7 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,532 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 3,300 | $2.01 | $6,633.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 2 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,233 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F3 · price: On February 22, 2017, the Reporting Person sold an aggregate of 3,300 shares of the Issuer's Common Stock at a weighted average price of $2.01 per share. The highest sale price for the Common Stock was $2.01 per share and the lowest sale price was $1.98 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:11 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 8,532 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006495 · doc4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining Restricted Stock Units ("RSUs") that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining Restricted Stock Units ("RSUs") that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:06 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 95,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003156 · doc4.xml · derivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2020-03-18 F1 · kind: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 14,800 | $2.44 | $36,112.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · nonDerivative · entry 4 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,991 F4 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F5 · price: On September 22, 2016, the Reporting Person sold an aggregate of 14,800 shares of the Issuer's Common Stock at a weighted average price of $2.44 per share. The highest sale price for the Common Stock was $2.47 per share and the lowest sale price was $2.41 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 34,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · derivative · entry 6 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,783 Underlying: Common Stock · 34,392 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 8,533 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · derivative · entry 5 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,532 Underlying: Common Stock · 8,533 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 34,392 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · nonDerivative · entry 3 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 8,533 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · nonDerivative · entry 2 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:34 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 1,483 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029948 · doc4.xml · nonDerivative · entry 1 De Paolantonio Ernest Robert · CIK 0001588538 · CFO, Secretary and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,866 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.